McKesson stock raises fiscal 2027 EPS outlook after Q2 growth

McKesson reported stronger fiscal 2027 second-quarter results on Wednesday, November 4, and raised its full-year adjusted earnings outlook. The company's earnings release said consolidated revenue reached USD 111.0 billion for the quarter ended September 30, up 8 percent from a year earlier.

McKesson stock traded at 947.10 euros on Lang & Schwarz at 17:07 CET on Friday, November 6, 2026.

Growth broadens across core operations

Diluted earnings per share increased to USD 10.44 from USD 8.92 in the prior-year quarter. Adjusted diluted EPS, a non-GAAP measure, rose 18 percent to USD 11.68 from USD 9.86.

Management attributed the operating progress to North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions. The company also cited a lower share count, with diluted weighted-average shares down 6 percent to 116.7 million.

Higher guidance raises expectations

McKesson lifted fiscal 2027 adjusted EPS guidance to USD 45.60 to USD 46.40 from USD 44.20 to USD 45.00. The new range implies adjusted EPS growth of 17 percent to 19 percent; excluding the prior-year Norway divestiture contribution and gains linked to the U.S. Oncology Network, management expects growth of 19 percent to 21 percent.

The company also expects fiscal-year revenue growth of 6 percent to 10 percent and adjusted operating-profit growth of 12 percent to 16 percent. For investors, the second half will show whether volume-led distribution growth and operating leverage can support the raised outlook while branded-pharmaceutical conditions remain a factor to monitor.

Investors can follow the real-time quote of McKesson stock on the company snapshot page.

The broader US market context is available in current S&P 500 market reports.

McKesson is scheduled to present at the Jefferies Global Healthcare Conference on November 17, 2026. More news and analyses on McKesson stock will track demand, margins and capital allocation.